 Matthew Sikora
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 10 | 2022 | 48 | 2.880 |
Why?
| | Breast Neoplasms | 24 | 2025 | 2131 | 2.540 |
Why?
| | Receptors, Estrogen | 10 | 2025 | 424 | 2.460 |
Why?
| | Wnt4 Protein | 4 | 2024 | 19 | 2.140 |
Why?
| | Antineoplastic Agents, Hormonal | 6 | 2025 | 158 | 1.590 |
Why?
| | Estrogens | 7 | 2025 | 342 | 1.490 |
Why?
| | Estrogen Receptor alpha | 9 | 2023 | 132 | 1.380 |
Why?
| | Drug Resistance, Neoplasm | 9 | 2025 | 744 | 1.120 |
Why?
| | Tamoxifen | 7 | 2021 | 200 | 0.830 |
Why?
| | Genital Neoplasms, Female | 1 | 2024 | 81 | 0.800 |
Why?
| | Genital Diseases, Female | 1 | 2021 | 27 | 0.730 |
Why?
| | Gene Expression Regulation, Neoplastic | 12 | 2025 | 1343 | 0.730 |
Why?
| | Genitalia, Female | 1 | 2021 | 38 | 0.730 |
Why?
| | MCF-7 Cells | 10 | 2021 | 115 | 0.720 |
Why?
| | Estradiol | 7 | 2023 | 486 | 0.700 |
Why?
| | Cell Proliferation | 12 | 2021 | 2337 | 0.690 |
Why?
| | Cell Line, Tumor | 17 | 2025 | 3168 | 0.690 |
Why?
| | Cell Cycle Proteins | 2 | 2021 | 578 | 0.680 |
Why?
| | Wnt3A Protein | 1 | 2019 | 10 | 0.660 |
Why?
| | Ovarian Neoplasms | 6 | 2024 | 487 | 0.660 |
Why?
| | Acyltransferases | 1 | 2019 | 53 | 0.650 |
Why?
| | Wnt Signaling Pathway | 2 | 2019 | 165 | 0.620 |
Why?
| | Women's Health | 1 | 2021 | 361 | 0.600 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 391 | 0.590 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2017 | 28 | 0.550 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2016 | 9 | 0.540 |
Why?
| | Serum | 1 | 2016 | 57 | 0.510 |
Why?
| | Signal Transduction | 8 | 2024 | 4812 | 0.490 |
Why?
| | Receptors, Androgen | 1 | 2016 | 143 | 0.490 |
Why?
| | Receptors, Glucocorticoid | 1 | 2016 | 148 | 0.480 |
Why?
| | Receptors, Progesterone | 1 | 2016 | 341 | 0.460 |
Why?
| | Neoplasm Invasiveness | 6 | 2020 | 477 | 0.450 |
Why?
| | Aromatase Inhibitors | 2 | 2018 | 51 | 0.450 |
Why?
| | Deep Brain Stimulation | 3 | 2020 | 125 | 0.430 |
Why?
| | Membrane Proteins | 1 | 2019 | 1105 | 0.420 |
Why?
| | Tumor Microenvironment | 3 | 2024 | 620 | 0.400 |
Why?
| | Cytochrome P-450 CYP2D6 | 4 | 2017 | 29 | 0.370 |
Why?
| | Gene Expression | 2 | 2014 | 1454 | 0.360 |
Why?
| | Benzoxazines | 1 | 2010 | 29 | 0.340 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 45 | 0.340 |
Why?
| | Paraffin Embedding | 1 | 2010 | 28 | 0.340 |
Why?
| | Genotyping Techniques | 1 | 2010 | 72 | 0.340 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2010 | 82 | 0.330 |
Why?
| | Female | 31 | 2025 | 68016 | 0.310 |
Why?
| | Androstane-3,17-diol | 1 | 2008 | 2 | 0.300 |
Why?
| | Gossypol | 1 | 2008 | 2 | 0.300 |
Why?
| | Humans | 40 | 2025 | 128019 | 0.300 |
Why?
| | Models, Biological | 2 | 2012 | 1689 | 0.290 |
Why?
| | Carcinoma, Ductal, Breast | 3 | 2022 | 82 | 0.270 |
Why?
| | Breast | 3 | 2022 | 152 | 0.250 |
Why?
| | Receptor, ErbB-2 | 2 | 2019 | 325 | 0.240 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2025 | 1 | 0.240 |
Why?
| | Antioxidants | 1 | 2008 | 542 | 0.230 |
Why?
| | Neoplasms | 2 | 2010 | 2460 | 0.230 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.220 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2024 | 68 | 0.220 |
Why?
| | DNA | 1 | 2010 | 1392 | 0.210 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 189 | 0.200 |
Why?
| | Selective Estrogen Receptor Modulators | 3 | 2017 | 26 | 0.190 |
Why?
| | Ligands | 1 | 2024 | 616 | 0.190 |
Why?
| | Sex Differentiation | 1 | 2021 | 10 | 0.190 |
Why?
| | Sexual Development | 1 | 2021 | 19 | 0.190 |
Why?
| | Mammary Glands, Human | 1 | 2021 | 64 | 0.180 |
Why?
| | Neuroma, Acoustic | 1 | 2021 | 41 | 0.180 |
Why?
| | RNA Interference | 2 | 2019 | 441 | 0.180 |
Why?
| | Protein Binding | 2 | 2016 | 2105 | 0.170 |
Why?
| | Genotype | 3 | 2017 | 1828 | 0.170 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 61 | 0.170 |
Why?
| | Uterus | 1 | 2021 | 206 | 0.170 |
Why?
| | Cell Survival | 2 | 2016 | 1073 | 0.160 |
Why?
| | Culture Media, Conditioned | 1 | 2019 | 108 | 0.160 |
Why?
| | Paracrine Communication | 1 | 2019 | 60 | 0.160 |
Why?
| | Snail Family Transcription Factors | 1 | 2019 | 17 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 377 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2021 | 2059 | 0.160 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 87 | 0.160 |
Why?
| | Coculture Techniques | 1 | 2019 | 225 | 0.160 |
Why?
| | Phthalazines | 1 | 2019 | 40 | 0.160 |
Why?
| | Gene Amplification | 1 | 2019 | 103 | 0.150 |
Why?
| | Gene Expression Profiling | 2 | 2018 | 1681 | 0.150 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 90 | 0.150 |
Why?
| | Estrogen Receptor Antagonists | 1 | 2017 | 2 | 0.150 |
Why?
| | Protein Transport | 1 | 2019 | 420 | 0.150 |
Why?
| | Endometriosis | 1 | 2018 | 48 | 0.150 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 381 | 0.140 |
Why?
| | Machine Learning | 2 | 2020 | 442 | 0.140 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2019 | 204 | 0.140 |
Why?
| | Transcriptome | 2 | 2021 | 879 | 0.140 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 569 | 0.140 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2017 | 39 | 0.140 |
Why?
| | Antineoplastic Agents | 1 | 2008 | 2041 | 0.140 |
Why?
| | Fishes | 1 | 2017 | 93 | 0.140 |
Why?
| | Piperazines | 1 | 2019 | 332 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2012 | 1943 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 431 | 0.130 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 1198 | 0.130 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2016 | 12 | 0.130 |
Why?
| | Androstenes | 1 | 2016 | 17 | 0.130 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 281 | 0.130 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1288 | 0.130 |
Why?
| | Cell Culture Techniques | 1 | 2018 | 344 | 0.130 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 115 | 0.130 |
Why?
| | Polymorphism, Genetic | 2 | 2017 | 638 | 0.130 |
Why?
| | Animals | 7 | 2021 | 34487 | 0.130 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2016 | 35 | 0.130 |
Why?
| | Proto-Oncogene Proteins | 1 | 2019 | 632 | 0.120 |
Why?
| | Reproduction | 1 | 2017 | 198 | 0.120 |
Why?
| | Algorithms | 2 | 2020 | 1609 | 0.120 |
Why?
| | Lipid Metabolism | 1 | 2018 | 491 | 0.120 |
Why?
| | Prognosis | 5 | 2024 | 3766 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1558 | 0.110 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 52 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 944 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 955 | 0.110 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1175 | 0.110 |
Why?
| | Mutation | 2 | 2021 | 3682 | 0.100 |
Why?
| | NF-kappa B | 1 | 2016 | 649 | 0.100 |
Why?
| | Smoking | 1 | 2019 | 1459 | 0.100 |
Why?
| | Mice | 5 | 2021 | 16574 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2021 | 2456 | 0.090 |
Why?
| | Phenotype | 2 | 2018 | 3039 | 0.090 |
Why?
| | Middle Aged | 8 | 2024 | 30812 | 0.090 |
Why?
| | Gynecomastia | 1 | 2010 | 6 | 0.090 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 82 | 0.090 |
Why?
| | Cyclopropanes | 1 | 2010 | 88 | 0.090 |
Why?
| | Alkynes | 1 | 2010 | 54 | 0.080 |
Why?
| | Microarray Analysis | 1 | 2010 | 120 | 0.080 |
Why?
| | Formaldehyde | 1 | 2010 | 57 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 940 | 0.080 |
Why?
| | Inflammation | 1 | 2020 | 2646 | 0.080 |
Why?
| | Polyunsaturated Alkamides | 1 | 2008 | 6 | 0.080 |
Why?
| | Cell Cycle Checkpoints | 2 | 2019 | 95 | 0.080 |
Why?
| | Pregnancy | 1 | 2021 | 6355 | 0.080 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 17 | 0.080 |
Why?
| | Arachidonic Acids | 1 | 2008 | 54 | 0.080 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1047 | 0.070 |
Why?
| | Genetic Association Studies | 1 | 2010 | 361 | 0.070 |
Why?
| | Hot Flashes | 1 | 2009 | 81 | 0.070 |
Why?
| | Oxidants | 1 | 2008 | 106 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1681 | 0.070 |
Why?
| | Acetylcysteine | 1 | 2008 | 141 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 356 | 0.070 |
Why?
| | Heterografts | 2 | 2019 | 128 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1020 | 0.070 |
Why?
| | Androgens | 1 | 2008 | 173 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 755 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2012 | 875 | 0.060 |
Why?
| | Cadherins | 2 | 2018 | 186 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1169 | 0.060 |
Why?
| | Reactive Oxygen Species | 1 | 2008 | 582 | 0.060 |
Why?
| | Survival Rate | 2 | 2020 | 1870 | 0.060 |
Why?
| | Patient Compliance | 1 | 2009 | 558 | 0.060 |
Why?
| | Aged | 5 | 2024 | 21892 | 0.060 |
Why?
| | Neoplasm Grading | 1 | 2024 | 283 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2010 | 873 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2010 | 4006 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2736 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2021 | 14404 | 0.050 |
Why?
| | Databases, Genetic | 1 | 2023 | 228 | 0.050 |
Why?
| | Biology | 1 | 2022 | 83 | 0.050 |
Why?
| | Microsurgery | 1 | 2021 | 70 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4853 | 0.040 |
Why?
| | Ubiquitination | 1 | 2020 | 98 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2009 | 2261 | 0.040 |
Why?
| | Apoptosis | 2 | 2019 | 2425 | 0.040 |
Why?
| | Proteolysis | 1 | 2020 | 162 | 0.040 |
Why?
| | Movement Disorders | 1 | 2019 | 52 | 0.040 |
Why?
| | Indazoles | 1 | 2019 | 65 | 0.040 |
Why?
| | Oxysterols | 1 | 2018 | 2 | 0.040 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2018 | 11 | 0.040 |
Why?
| | Adherens Junctions | 1 | 2018 | 26 | 0.040 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 1 | 2018 | 57 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2019 | 169 | 0.040 |
Why?
| | Collagen Type I | 1 | 2018 | 117 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 451 | 0.040 |
Why?
| | Piperidines | 1 | 2019 | 190 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1199 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 930 | 0.030 |
Why?
| | Pharmacogenomic Variants | 1 | 2017 | 35 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2018 | 444 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2019 | 201 | 0.030 |
Why?
| | Adult | 4 | 2021 | 35176 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 371 | 0.030 |
Why?
| | RNA, Neoplasm | 1 | 2016 | 87 | 0.030 |
Why?
| | Risk Factors | 2 | 2020 | 9696 | 0.030 |
Why?
| | Length of Stay | 1 | 2021 | 1114 | 0.030 |
Why?
| | DNA, Neoplasm | 1 | 2016 | 159 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 504 | 0.030 |
Why?
| | Mice, SCID | 1 | 2016 | 350 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 851 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 608 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2018 | 495 | 0.030 |
Why?
| | Alleles | 1 | 2017 | 842 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1934 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1262 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 809 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 933 | 0.030 |
Why?
| | Genome | 1 | 2016 | 277 | 0.030 |
Why?
| | Male | 3 | 2019 | 62757 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 419 | 0.030 |
Why?
| | Registries | 1 | 2019 | 1873 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1663 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2598 | 0.020 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2010 | 12 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2010 | 187 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 509 | 0.020 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 1 | 2008 | 6 | 0.020 |
Why?
| | Microsomes | 1 | 2008 | 30 | 0.020 |
Why?
| | Hydroxylation | 1 | 2008 | 32 | 0.020 |
Why?
| | Mice, Nude | 1 | 2010 | 675 | 0.020 |
Why?
| | Epoxy Compounds | 1 | 2008 | 32 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2669 | 0.020 |
Why?
| | Arachidonic Acid | 1 | 2008 | 114 | 0.020 |
Why?
| | Endocannabinoids | 1 | 2008 | 39 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1227 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2134 | 0.020 |
Why?
| | Young Adult | 1 | 2019 | 12281 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 10110 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3009 | 0.010 |
Why?
| | Mitochondria | 1 | 2008 | 847 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 5378 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 6479 | 0.010 |
Why?
| | Prospective Studies | 1 | 2009 | 7035 | 0.010 |
Why?
| | Brain | 1 | 2008 | 2615 | 0.010 |
Why?
|
|
Sikora's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|